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Abstract 
 In this paper we analyze the evolution of the role of the sales manager 
and of the sales force in a relational perspective of value creation in business-
to-business contexts, included in the sale of prescription drugs, in Italy. The 
empirical research and the strategic implications are to highlight the 
importance of the customer-supplier relationship in business to business 
context and the role of the sales force in managing long-lasting relationships 
with customers. The work ends with the study of a task force model for easier 
market access by pharmaceutical companies and an expected value 
proposition through the sharing of knowledge and the creation of partnerships. 
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1. Introduction and purpose of the research 
The pharmaceutical sector in Italy is experiencing moments of profound 
turbulence and competitive discontinuity never experienced in the past as a 
result of major environmental transformations including: the need for a 
reduction in health spending by the national and local health system, the 
difficulty of access to medical class and the contraction of productivity of the 
networks of scientific informants, the affirmation of generic drugs2 and the 
growing role of the local health system and its actors as a key customer3. 
Today, these phenomena force the pharmaceutical industry to review its 
marketing & sales strategies for access to the increasingly restrictive drug 
market. In particular, the regionalistic reform of the national health system has 
led to an increase in access barriers for the product, forcing the pharmaceutical 
                                                          
2 Introduced on the market through Law 425 of 8 August 1996, conversion of the D.L. 323 of 
20 June 1996. 
3 For further information on the pharmaceutical sector, see also: Vallega, 1996; Brusoni, 1999; 
Smith, 2001; Frezza, 2005. 
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company to consider a plurality of new interlocutors between decision makers 
and influencers; not just doctors4, but also pharmacists5 and technical, 
administrative, institutional and public figures (Data and Mariani, 2015). 
Therefore, in order for pharmaceutical companies to recover the profitability 
of past years, it is necessary, in particular, to differentiate the commercial 
approach and the contents of communication through a commercial 
organization that guarantees better access to the market of the drug (Market 
Access) and is based on a new structure able to consider as a client not only 
the medical profession but also all the actors that determine the development 
of the local health system through a consultancy relationship, based on a strong 
mutual trust and a high contribution in terms of problem solving, that goes 
beyond the scientific aspects and that embraces all the problems concerning 
the health and / or the profession of the doctor. To do this it is necessary to 
activate more and more decision-making processes that integrate people of 
different units - marketing and sales - into teams and structuring, making 
homogeneous and shareable the knowledge, that is information and 
managerial models (Drey and Pompini, 2005). All this can only be achieved 
through a transition, especially in the sales management, from a transactional 
approach (Kotler, 1976, Borden, 1964, Varaldo and Stanton, 1987) to a 
relational and therefore through an evolution of the role of sales manager and 
sales force. The first attempt of the company sees the birth of Key Account 
Manager (KAM) and Regional Account Manager (RAM). These figures, in 
the pharmaceutical sector, are destined to merge, in the very near future, under 
the direction of the Market Access Manager (Falotico and Mariani, 2014). In 
light of these brief introductory considerations, the present work, without 
having exhaustive pretenses for such a vast topic, aims to achieve the 
following objective: analysis of the evolution of the role of sales manager and 
sales force in a relational perspective of value creation in business-to-business 
contexts, mainly linked to the sale of prescription drugs, for the 
implementation of effective strategies of approach to Market Access (MA) by 
the pharmaceutical company. 
  
2. Theoretical background on the evolution of the role of Sales 
Management in a relational perspective of value creation 
 The study of relationships with its customers is a long-standing topic 
in marketing literature, in particular with reference to the role that 
                                                          
4 For prescription drugs, the decision to use, and therefore to consumption, revolves around 
the figure of the doctor who is the prevalent communication target of pharmaceutical 
marketing, in the case of self-medication drugs is the patient (Gianfrate, 2008). 
5 Pharmacists are now able to influence the sale of both self-medication and generic drugs by 
working, thanks to the high professional competence, a strong selection of brands at the 
entrance and adequate advice to the patient at the exit (Lugli.e Cristini, 2007). 
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relationships play in improving competitive performance in the markets in 
which they are considered companies (Hakansson, 1982, Jackson, 1985; 
Gummesson, 1987, 1998 and 1999, Hakansson and Snehota, 1989, Morgan 
and Hunt, 1999, Vicari, Bertoli, Busacca, 2000). As is known, the relationship 
marketing deals with social, dyadic and network relations, deriving from 
processes of exchange of time, which foster relationships of cooperation and 
a real partnership between sellers and  buyers siness especially in the business 
to business markets ( Anderson and Narus, 1984, Ferrero, 1992, Snehota and 
Tunisini, 1994, Gronroos, 1994, Castaldo, 1994). In business-to-business 
environments6, communication, through which the process of mutual 
adaptation takes place between purchasing and supplying companies, is the 
indispensable prerequisite for the continuity of long-term relationships 
(Fiocca, 2002). In particular, the personal and interactive dimension of BtoB 
communication constitutes the real big difference compared to any other type 
of business. The relational matrix literature emphasizes the contribution of 
sellers in the development of long-term relationships between the purchasing 
company and the seller with consequent increase in competitive advantage and 
company performance (William, Attaway, 1996, Marshall , Moncrief and 
Lassk 1999; Flaherty, Dahlstrom, Skinner, 1999, Palmatier RW et al., 2007, 
Sisti, Guenzi and Caiozzo, 2015). Empirical studies highlight the importance 
of interpersonal relationships between seller and buyer by demonstrating how 
the supplier's ability to create and maintain successful relationships with 
customers is completely dependent on the attitudes, skills and behaviors of 
their vendors (Langerak, 2001; Weitz and Bradford, 1999 ), which generate 
and increase the trust of the customer (Wilson, 1995) towards the supplier 
company as a whole (Doney and Cannon, 1997) positively influencing the 
satisfaction, the prospective fidelity (Liu, and Leach, 2001), the perceived 
quality, increasing the intention to repurchase and the desire to recommend 
the supplier to other potential customers (Foster and Cadogan, 2000). The 
seller is increasingly required to become "micro-marketing managers" 
(Lazzaro, 1995), to create value with and for customers (De Vincentis and 
Rackham, 1996), to develop with the latter a partnership relationship, to 
acquire skills for the proper management of the sales team, as well as the 
development of market analysis and planning skills (Wilson, 1993). In 
particular, it is affirmed the opportunity to reconfigure the commercial 
processes moving from an approach based on hard selling to one definable as 
smart selling (Sujan, Weitz and Kumar, 1994; Kohli, Shervani and 
Challagalla, 1998) in which sellers develop learning. and ability to adapt 
according to the specific characteristics of the interaction with the customer 
                                                          
6 For a general study of the business to business markets, see also: Giulivi, 2001; Fiocca, 
Snehota and Tunisini, 2003, Foglio, 2014. 
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considering the role of co-producers of the same (Jones et al., 2005). 
Furthermore, there is also a change in the activity of sales management, 
especially in the aspects concerning the selection and training of sellers, and 
in those concerning the evaluation and control systems (Weitz.and Bradford, 
1999) as if the success of the sales, and therefore the improvement of company 
performance, depends on the seller is also true that this success is the result of 
the ability of the sales manager and the relationship between this and the 
sellers who make him head. In fact, sales management is an integral part of 
many performance models (Brown, & Peterson, 1993; Churchill et al., 1985; 
Weitz, Sujian & Sujian, 1986). In particular, Sales Management Effectiveness 
(achievable through the following antecedents: construction of close 
relationships with sellers, frequent work of the sales manager with the sales 
force, control of the same, good management of the relationship with the 
customer, motivation of sellers through remuneration) it is a source of 
competitive advantages and has a positive effect on the seller's commitement 
at the universal level and irrespective of the national culture (Murph and Li, 
2012). Finally, sales managers are the link between the vision, the values of a 
company and the sales force (Wieseke et al., 2009). The greater the tendency 
of sales managers to assign to the sales force objectives of maintaining and 
developing the relationship with the current customer, the greater is the 
perspective of relational orientation of the company (Gronroos, 1990; Kalwani 
and Narayandas, 1995). On the basis of these assumptions, a construct of 
Commercial Orientation of the Company (Guenzi, 2000) was elaborated by 
Guenzi, which allowed to highlight the link between the relational activity 
carried out by the sales force and the set of factors able to significantly 
influence this activity: the complexity of the customers and the heterogeneity 
of their needs (from the external side), the complexity of the company's offer, 
the inter-functional coordination between marketing and sales (Kahn, 1996, 
2001; Slater and Olson, 2000; al., 2001; Guenzi and Troilo, 2006) and the 
importance given to the sales force in acquiring competitive advantage (from 
the inside). On the one hand, this involves a profound change in the wealth of 
individual skills and competencies of sellers, a reformulation of the selection, 
training, incentive and control policies of the sales force and, on the other, a 
strategic rethinking in terms of the underlying commercial orientation. In 
recent decades, the need to systematically manage lasting relationships with 
customers, in highly dynamic and competitive contexts, has led to a revision 
and redesign of the logic and tools of customer management served through 
the creation of a new managerial model: the Key Account Management. The 
latter is a managerial philosophy (Ojasalo, 2001) which is characterized by its 
systematic nature, the high degree of coordination, interaction and 
transversality with respect to the various company functions, with the main 
objective of building strong relationships, long-lasting and above all profitable 
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with a selected group of customers, giving them a specific term such as 
national account, global account (Shapiro and Posner, 1976), major account 
(Stevenson, 1980; Barret, 1986) and subsequently key account (Fiocca, 1982) 
or strategic account (Millman and Wilson 1995, Pardo et al. 1995, Guenzi 
2002), offering them a special and personalized treatment (McDonald et al. 
1997). Essential prerequisites for the success of this managerial model are: the 
sharing of intentions between customer and supplier that depends, in turn, on 
the stage of the relationship, the commitment of the management called to 
support the process, the implementation of a specific organizational structure 
and a company information system capable of ensuring integrated and 
coordinated customer management through effective and efficient sharing of 
knowledge (Sisti MA, 2004). The literature on relationship marketing, sales 
management and account management allow us to build a path of development 
for the management of the MA of the pharmaceutical company. 
 
3. Management of Market Access through Sales Management 
Effectiveness: results of an empirical study 
 The management of pharmaceutical drug access to the market is of 
strategic importance if we consider that, according to some previous estimates 
provided by EFPIA7, Italy shows an average delay of 326 days, compared to 
other European countries, between the request for marketing authorization and 
access to the patient, considering both the hospital and the retail distribution. 
A more recent contribution estimates the time of access to medicines in Italy 
in the period 2015-2017 in 258 days (Lidonnici et al., 2018). This delay is the 
result of a rigorous control in the pricing and refund procedures of drugs by 
the AIFA (Italian Medicines Agency) as the only national body authorized to 
place medicines on the market. This input takes into  consideration both the 
impact of the drug on the state budget, the comparison with the prices of other 
European countries and the cost-benefit ratio for the most innovative drugs. 
National marketing is not, therefore, necessarily equivalent to regional and 
local access, which is independently assigned by each decentralized authority 
with different methods and access difficulties. In the literature there is a recent 
work that analyzes the state of the pharmaceutical industry with respect to the 
issue of MA in Italy (Jommi, Otto, Armeni., De Luca, 2012). In particular, the 
results of this study highlight that the access of the drug to the market is mainly 
associated with a public business activity, which consists in the negotiation of 
prices and reimbursement of drugs, rather than a commercial activity in the 
sense side. The problem related to MA has led to organizational changes that 
have mainly affected the largest pharmaceutical companies with a prevalent 
retail activity. This change has resulted in the creation of an inter-functional 
                                                          
7 EFPIA (Market Access Delays in http://www.efpia.org  03/12/2012). 
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area of MA in which units from the marketing function and sales function are 
involved or in the creation of an autonomous MA unit with an added staff for 
this function and a director who assumes above all public business functions. 
Since the aim of the research work is to verify how much the new 
organizational structure contributed to the evolution of the role of sales in 
relational terms, it was decided to associate a qualitative analysis to a 
descriptive study (Mari, 1994; Yin, 2002) which finds justification in the 
coherence with the objective of study and with the multiform and complex 
nature of the phenomenon investigated. This analysis was conducted through 
an interview with a key informant within the company WINCH s.r.l. of Milan 
specialized in the provision of training services in the pharmaceutical field in 
Italy8, with particular reference to the MA problem, and subsequently through 
the formulation of a case study made possible thanks to the valuable 
contribution of the Head of Public Affairs & Market Access in Boehringer 
Ingelheim Italy (BIT). 
 The results of the interview with the key informant show how the 
pharmaceutical companies, through an organization of MA, have two 
fundamental objectives: 1. to know the minimum detail and at all levels 
(national, regional and local) the organization and the logic of the supply chain 
of subjects involved in the process of acquisition of a drug for hospital or 
widespread use; 2. to create specialized operative units able to operate, 
alongside Marketing & Sales, Medical and Regulatory, in order to facilitate 
the introduction of drugs into the national, regional and local health system. 
The majority of pharmaceutical companies have selected, for roles with 
different names (LAM - Local Access Manager, RAM - Regional Access 
Manager, KAM - Key Account Manager etc.), figures coming from the Sales 
Department, assigning their Job Descriptions and generic contact lenses with 
institutional or administrative figures of the Health System, often completely 
detached from the actual needs / opportunities of synergy with the other 
departments involved. It was therefore found that for the relational aspects, 
there is still work to be done on the creation of the composite operating teams 
(MA, Regulatory, Medical, Marketing, Sales) and the sharing of objectives, 
due to the presence of uncoordinated overlaps of activities on different targets 
by different subjects for a common goal. The situation in Boehringer 
Ingelheim Italy is different. The Group, based in Ingelheim, Germany, is one 
of the top twenty pharmaceutical companies in the world, and in 2017 recorded 
net sales of € 18.1 billion. Within the group, Boehringer Ingelheim Italia (BIT) 
develops its business in the Milan, Reggello and Fornovo San Giovanni 
offices. The commercial sector is divided into three Divisions: Prescription 
and Hospital Medicines Division, Self-Grade and Wellness Products Division, 
                                                          
8 (www.winch.it). 
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Veterinary Division. With a net turnover of € 455 million (+ 28% compared 
to the previous year), BIT is one of the top 20 pharmaceutical companies 
nationwide. In this reality, the MA is an activity that aims to ensure access to 
prescription drugs to patients who need it. This activity is based on two levers: 
producing not only clinical evidence, but also economic sustainability right 
from the pre-launch phases, that is those that precede the placing on the market 
(which coincides with the publication in the Official Journal), and the bringing 
these evidences to stakeholders direct and indirect decision makers, trying to 
meet the expectations not only of clinicians but also of national and regional 
payers, differentiating strategies for territories and classes of doctors through 
a MA plan that provides for the analysis of the different regional situations in 
terms of opportunities and barriers (starting from regional epidemiological 
data for an analysis of local scenarios) with the identification of action 
priorities. The diversification of strategies for classes of customers has as its 
sole effect the different declension of the message according to the interlocutor 
(General Manager, Health Director, Administrative Director, 
Pharmacologists, Patients Association, Policy Makers, etc.). The MA function 
is now included in the "Prescription Medicine" area, but for the Institutional 
part of Public Affairs it is functional in Staff with the General Management. It 
is composed of 5 Regional Affair Managers (RAM) 9 and an institutional 
relations manager, a Health Economist & Pricing Manager supported by a 
Pricing & Reimbursement Manager and a relationship manager with AIFA, a 
regional Market Access supported by 4 project management managers and of 
relationships with patient associations and a structure of 16 Key Account 
Managers (KAM) 10 plus two coordinators who deal with customers in the 
area. The fundamental requirement for the success of this organization is the 
transfer of knowledge and the consolidation of skills through rigorous training 
and assessment courses as well as a strong integration with the other 
departments of the company. The model of skills related to the human 
resources for the MA is structured as follows: technical-professional skills, 
managerial skills and transversal skills (organizational awareness, Problem 
Solving, Teamworking). The objectives achieved through the MA are: 1. the 
insertion of the drug in lists of various level and the speed of access in the 
same (for example the drug "Pradaxa" has been included in 90% of the 
regional list in less than a year) ; 2. Drug-economy studies to encourage the 
appropriateness of pharmaceutical spending related to the company's 
                                                          
9 The RAM deal with Policy Makers (Ministry, National Institutional Institutions, Regional 
Assessments, DG of AS), Institutional Stakeholders and Patient Associations. 
10 The KAM take care of the regional functional level (Healthcare General Directions, 
Regional Agencies, Pharmaceutical Departments ..) and Local (DG, DA, DS, Hospital 
Pharmacists, Clinical Pharmacologists, etc.). The Kam record the contacts in a CRM database 
whose interface is shared with the sales force. 
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products; 3. Partnership with public subjects for the realization of projects (for 
example the project on organizational well-being with "Fiaso"). 
 
4. An operational model of Market Access task forces and 
management implications 
The relational perspective of the sales force should not be experienced by 
the sales managers of pharmaceutical companies in a defensive way, but rather 
as an opportunity for strategic growth able, therefore, to bring potential 
benefits such as: increasing customer penetration, development of cross 
selling, the increase of the knowledge of the market through the acquisition of 
detailed information on customers, competitive distance. These benefits could 
be achieved through sales managers able to carry out internal sales team 
coordination activities able to create and transfer value to customers. From the 
data gathered from the interviews, the opportunity has emerged to create an 
operative model for the implementation of a MA task force by the 
pharmaceutical company that focuses on key technical and transversal skills11. 
The following figure shows, by way of example, a reference model for the 
Regional Market Access Manager.  
Fig. 1: Regional Market Access Manager model 
                                                          
11 Transversal skills, unlike technical / specialist skills, can be extended to all people and refer 
to knowing how to be and include a set of emotional, cognitive and social skills (Frasson D., 
2011, page 39). ISFOL groups them into three macro-categories concerning the ability to 
diagnose, relate and deal with (Di Francesco G., 1998). 
ROLE ACTIVITIES AND RESPONSABILITIES 
 
 
Ensures the management of 
activities to access the market of 
new products and the prices to be 
applied in the assigned territories, 
in connection with local / regional 
health authorities and scientific 
associations 
It handles relationships with local health authorities and 
scientific associations 
It manages the relationship with the hospital management 
and provides indications of drug-economy 
Identify the Decision Makers 
Map the current situation of the company in relation to the 
PTOR / PTO 
Coordinates the production of detailed plans 
It supports the bidding process and the tender process by 
developing appropriate proposals 
It collaborates in the preparation of the PTOR files and 
prepares / presents the PTO file 
It supports the central functions, updating them on the 
territorial dynamics of Market Access 
TECHNICAL-SPECIALIST 
SKILLS 
MANAGERIAL / TRANSVERSAL SKILLS 
Relational Cognitive and realization 
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 Through this operational model of MA task force implementation, the 
pharmaceutical company could have the opportunity to develop competitive 
advantages through the implementation of innovative partnership projects 
with healthcare companies and regional health institutions such as: 1. 
Implementation of pathology networks and rationalization of PDTA12 for 
chronic diseases; 2. Creation of functional aggregations in primary care; 3. 
Creation of communication areas for knowledge sharing in the specialist field 
(Scientific Social Network); 4. Implementation of drug-economy studies to 
encourage the appropriateness of pharmaceutical spending; 5. Dissemination 
of tele-assistance projects to make the most of the large sector of chronic 
diseases.  
 The critical success factor for the implementation of an effective 
Market Access task force, according to the operational model shown below, is 
the investment by pharmaceutical companies in human capital and in 
particular in life-long learning (Redding 1996). Previous studies have 
highlighted the complementarity between three main components of human 
capital: early ability, formal education and training (Ariga and Brunello, 2006; 
Arulampalam et al., 2004)). In particular, Scicchitano (2010) highlights how 
the strong relationship between heterogeneous human capital (education and 
job-training) and research and development (R&D) is important for innovation 
and economic growth as well as for the achievement of the strategy’s main 
aims. 
 The research presents some limitations that need to be emphasized in 
order to stimulate further study of the work in the near future. First of all, the 
                                                          
12 The Diagnostic Therapeutic Care Paths are multi-professional and interdisciplinary 
assistance plans built for specific patient categories, prepared and used by healthcare 
providers, in order to improve the clinical results and the quality of the services offered to the 
customer, with a view to rationalization. of expenditure (Valentini I., Career Paths, Disease 
Management, GIt Diabetol Meteb, 27, 2007, pp. 65-68, in www.gidm.it/pdf/2-
2007/Editoriale.pdf (24/09/2012). 
Hospital-Territory organization 
composition 
Pharmaceutical market rules 
Knowledge of local market 
Pharmaco-economics 
Business Analysis Project 
Managem. 
Skills on the subject of public 
officials 
Knowledge of purchase 
procedures 
Knowledge of stakeholders 
involved in the dynamics of 
Market Access 
Propensity to relationships 
Negotiation 
Responsibility 
Influence 
Situational leadership 
Assertiveness 
Teamworking 
Partnerships 
Understanding needs 
Focus results 
Problem Solving / Decision 
Making 
Process management 
Self confidence 
Innovation guidelines 
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work has a descriptive and exploratory nature and takes into consideration 
only one case study. In particular, we could investigate the commercial 
orientation of pharmaceutical companies in order to verify the coherence 
between vision, values and objectives as well as verify the link between 
external and internal factors to the pharmaceutical company with the activities 
of the sales force also evaluating key competences. Finally, we could analyze 
the sales person equity (Fiocca, 2002) through a direct survey of the most 
important customers of pharmaceutical companies in order to verify the level 
of trust, satisfaction and prospective loyalty creating the conditions for a 
partnership and the maintenance of competitive advantages in the long term. 
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